Ironwood Pharmaceuticals (IRWD) Income from Continuing Operations (2010 - 2026)

Ironwood Pharmaceuticals has reported Income from Continuing Operations for 17 years, with the latest figure at 40772000.0 in Q1 2026.

• Quarterly Income from Continuing Operations rose 209.06% year-over-year to 40772000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 58972000.0 (down 149.05% YoY) and the FY2025 annual result came in at 137130000.0, down 189.39% from the prior year.
• Income from Continuing Operations rose to 40772000.0 in Q1 2026 per IRWD's latest filing, from 163423000.0 in the prior quarter.
• Over five years, Income from Continuing Operations peaked at 154796000.0 in Q4 2024 and troughed at 1089522000.0 in Q2 2023.
• A 5-year average of 50914705.88 and a median of 23599000.0 in 2025 frame the typical range for Income from Continuing Operations.
• The sharpest annual moves came in 2023 and 2025: Income from Continuing Operations tumbled 3038.3% in 2023, then jumped 2844.07% in 2025.
• Over 5 years, Income from Continuing Operations stood at 126514000.0 in 2022, then plunged by 215.0% to 145491000.0 in 2023, then jumped by 206.4% to 154796000.0 in 2024, then plunged by 205.57% to 163423000.0 in 2025, then surged by 124.95% to 40772000.0 in 2026.
• According to Business Quant data, Income from Continuing Operations over the past three periods registered 40772000.0, 163423000.0, and 40080000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.